How much funding has Optieum Biotechnologies raised?

Optieum Biotechnologies has raised $12.6M in total funding, most recently a Series A round.

Who are Optieum Biotechnologies's investors?

Optieum Biotechnologies's investors include Saisei Ventures, ANRI, Keio Innovation Initiative, Real Tech Holdings, Iyogin Capital.

When was Optieum Biotechnologies founded?

Optieum Biotechnologies was founded in 2020.

Where is Optieum Biotechnologies headquartered?

Optieum Biotechnologies is headquartered in Toon, Japan.

What industry is Optieum Biotechnologies in?

Optieum Biotechnologies operates in Biotech, Healthcare.

How many employees does Optieum Biotechnologies have?

Optieum Biotechnologies has 1-10 employees.

Optieum Biotechnologies

Revolutionizing Immunity – Optimizing CAR-T for Breakthrough Therapies

Toon, Japan · Founded 2020 · $12.6M raised

Biotech

Healthcare

Headquarters: Toon
Employees: 1–10
Founded: 2020
Business Model: B2B

Website: optieumbio.com
Total Funding: $12.6M
Last Round: $10.0M Series AJan 2025
Rounds: 2

About

Optieum Biotechnologies Inc. is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for solid tumors and hematological malignancies. The company's core platform, the Eumbody System, uses empirical methodologies to identify optimized CAR constructs by dynamically harmonizing scFv sequences, enhancing T-cell functional capabilities including proliferative capacity, antigen escape prevention, and tumor reactivity. Optieum's lead program targets FAPa (cancer-associated fibroblasts in solid tumors) with additional programs targeting CD19. Founded in 2020, the company secured a JPY 290 million seed round in 2021, a JPY 1.33 billion Series A in January 2025, and a grant of up to $39 million from Japan's AMED in March 2025. The company is associated with Ehime University and has CDMO partnerships with Genezen and Cellipont Bioservices.

Summary

Optieum Biotechnologies is a Biotech company based in Toon, Japan, founded in 2020. It has raised $12.6M in total across 2 rounds, most recently a $10.0M Series A round in Jan 2025. Investors include Saisei Ventures, ANRI and Keio Innovation Initiative.